UroGen Pharma Ltd

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 269.23, 419.77, 553.96, 706.92, 845.48 ], "ebit_estimate": [ -7.97, 108.02, 225.74, 385.65, 514.05 ], "ebitda_estimate": [ -15.28, 55.22, 120.75, null, null ], "net_income_estimate": [ -46.69, 65.78, 175.05, 311.61, 405.61 ], "per_share_eps_estimate": [ -0.92, 1.37, 3.52, 5.41, 6.94 ], "eps_nri_estimate": [ -0.85, 1.23, 3.16, 5.41, 6.94 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -46.51, 72.07, 186.93, 340.95, 458.05 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null ], "gross_margin_estimate": [ 89.93, 89.97, 89.8, 90, 90 ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 0, 28.15, 10.97, 7.14, 5.56 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "69.89", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 69.89, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 0.39, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 62.15, 73.32, 82.81, 85.53, 97.82, 109.18, 118.54 ], "ebit_estimate": [ -4.8, 4.91, 12.18, 8.75, 19.65, 26.78, 33.2 ], "ebitda_estimate": [ -3.29, 4.53, 3.67, -1.93, null, null, null ], "net_income_estimate": [ -14.94, -6.43, -0.22, 3.53, 11.55, 18.5, 24.78 ], "per_share_eps_estimate": [ -0.3, -0.13, -0.01, 0, 0.18, 0.34, 0.48 ], "eps_nri_estimate": [ -0.29, -0.1, 0.03, -0.04, 0.18, 0.34, 0.48 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -15.58, -5, 3.67, 5.17, 10.1, 15.37, 20.57 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 89.6, 89.6, 89.93, 90.45, 90.45, 90.45, 90.45 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 940.73, 75.63, 38.65, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "69.89", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 69.89, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 0.39, "future_operating_cash_flow_per_share_estimate_growth": null }